Related Experiment Video
Updated: Apr 18, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
13.8K
Prostaglandin-associated periorbitopathy in latanoprost users
Shunsuke Nakakura1, Minamai Yamamoto1, Etsuko Terao1
1Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
Clinical Ophthalmology (Auckland, N.Z.)
|January 8, 2015
Summary
Latanoprost ophthalmic solution can cause prostaglandin-associated periorbitopathy (PAP) signs like eyelid changes. While these effects were observed, their occurrence rates in glaucoma patients appear relatively low.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Glaucoma treatment often involves prostaglandin analogues.
- Prostaglandin-associated periorbitopathy (PAP) is a known side effect of these treatments.
Purpose of the Study:
- To investigate the incidence of prostaglandin-associated periorbitopathy (PAP) in glaucoma patients treated with latanoprost ophthalmic solution.
Main Methods:
- Evaluated 22 treatment-naïve glaucoma subjects using latanoprost for over a year.
- Compared pre-treatment and post-treatment digital photographs for four PAP signs and supplemental eyelid side effects.
- Assessed signs by three independent observers, requiring unanimous agreement for a positive result.
Main Results:
- No apparent PAP signs in 54.5% of subjects.
- Deepening of the upper eyelid sulcus (DUES) observed in 13.6%, eyelid pigmentation and lower eyelid bag flattening in 9.0% each.
- Other signs occurred in less than 5% of subjects; no significant association with age, sex, or therapy duration was found.
Conclusions:
- Latanoprost can induce various signs of prostaglandin-associated periorbitopathy (PAP), including eyelid changes.
- The observed rates of these side effects were relatively low in the studied population.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:25Glaucoma: Overview
1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
01:28Angle Closure Glaucoma: Treatment
1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
01:23Ophthalmic Drug Delivery Systems
252
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
252